SAN

81.58

+0.84%↑

UCB

246.7

+2.41%↑

SHL.DE

36.03

-2.25%↓

ARGX

683.6

+0.97%↑

VIE

35.56

+0.79%↑

SAN

81.58

+0.84%↑

UCB

246.7

+2.41%↑

SHL.DE

36.03

-2.25%↓

ARGX

683.6

+0.97%↑

VIE

35.56

+0.79%↑

SAN

81.58

+0.84%↑

UCB

246.7

+2.41%↑

SHL.DE

36.03

-2.25%↓

ARGX

683.6

+0.97%↑

VIE

35.56

+0.79%↑

SAN

81.58

+0.84%↑

UCB

246.7

+2.41%↑

SHL.DE

36.03

-2.25%↓

ARGX

683.6

+0.97%↑

VIE

35.56

+0.79%↑

SAN

81.58

+0.84%↑

UCB

246.7

+2.41%↑

SHL.DE

36.03

-2.25%↓

ARGX

683.6

+0.97%↑

VIE

35.56

+0.79%↑

Search

Laboratorios Farmaceuticos Rovi SA

Fechado

SetorSaúde

84.6 -1.11

Visão Geral

Variação de preço das ações

24h

Atual

Mín

84.25

Máximo

86.1

Indicadores-chave

By Trading Economics

Rendimento

-33M

43M

Vendas

7.9M

218M

P/E

Médio do Setor

36.483

60.328

EPS

0.834

Margem de lucro

19.539

Funcionários

1,950

EBITDA

-21M

63M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+1.58% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

427M

4.4B

Abertura anterior

85.71

Fecho anterior

84.6

Sentimento de Notícias

By Acuity

50%

50%

179 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de abr. de 2026, 00:00 UTC

Notícias Principais

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 de abr. de 2026, 23:33 UTC

Ganhos

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 de abr. de 2026, 22:40 UTC

Ganhos

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 de abr. de 2026, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 de abr. de 2026, 21:11 UTC

Ganhos

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 de abr. de 2026, 21:01 UTC

Ganhos

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 de abr. de 2026, 23:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de abr. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 de abr. de 2026, 23:34 UTC

Conversa de Mercado
Notícias Principais

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 de abr. de 2026, 23:16 UTC

Ganhos

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 de abr. de 2026, 23:15 UTC

Ganhos

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 de abr. de 2026, 22:54 UTC

Ganhos

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 de abr. de 2026, 22:54 UTC

Ganhos

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 de abr. de 2026, 22:52 UTC

Ganhos

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 de abr. de 2026, 22:51 UTC

Ganhos

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 de abr. de 2026, 22:31 UTC

Ganhos

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 de abr. de 2026, 22:31 UTC

Ganhos

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 de abr. de 2026, 22:30 UTC

Ganhos

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 de abr. de 2026, 22:30 UTC

Ganhos

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 de abr. de 2026, 22:29 UTC

Ganhos

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 de abr. de 2026, 22:28 UTC

Ganhos

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 de abr. de 2026, 22:28 UTC

Ganhos

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 de abr. de 2026, 22:27 UTC

Ganhos

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 de abr. de 2026, 22:06 UTC

Conversa de Mercado
Ganhos

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 de abr. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 de abr. de 2026, 21:47 UTC

Ganhos

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 de abr. de 2026, 21:37 UTC

Ganhos

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 de abr. de 2026, 21:34 UTC

Ganhos

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 de abr. de 2026, 21:29 UTC

Ganhos

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 de abr. de 2026, 21:20 UTC

Conversa de Mercado
Ganhos

Tesla Expands Manufacturing to Chips -- Market Talk

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

1.58% parte superior

Previsão para 12 meses

Média 86.75 EUR  1.58%

Máximo 90 EUR

Mínimo 83.5 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

1

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

51.1 / N/ASuporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

179 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat